PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSUMM.L Share News (SUMM)

  • There is currently no data for SUMM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sector movers: AstraZeneca, Shire lift pharma stocks on upbeat guidance

Tue, 14th Jan 2014 15:22

Decent gains from AstraZeneca and Shire gave the pharmaceuticals sector a boost on Tuesday as both firms gave confident outlooks.At the JP Morgan Healthcare Conference in San Francisco, AstraZeneca Chief Executive Pascal Soriot said he expects the company to return to growth sooner than analysts currently predict. He said that new incoming drugs from the company's portfolio as well as the buy-out of Bristol-Myers Squibb from their diabetes alliance should help halt a decline in sales. Sales have been under pressure over the last year due to a number of patent expiries and competition from generic versions of its drugs."AstraZeneca now expects 2017 revenues to be broadly in line with 2013 revenues," he said.The share price was 2.5% higher at around 3,755p by 15:50 on Tuesday.Toby Morris, Senior Sales Trader at CMC Markets, said: "The update comes ahead of a 2013 number release on Feb 6th, with a strong pipeline versus 12 months ago providing a boost in optimism and sending the stock higher."Shire, meanwhile, raised its earnings guidance for 2013 to the upper end of previous expectations, pushing the stock up 2.4% to 2,981p.Shire shares spiked immediately higher this afternoon as the Dublin-headquartered company put out a short statement from Chief Executive Flemming Ornskov that confirmed a strong finish to the year.Ornskov, who had been addressing investors at the same conference in San Francisco as AstraZeneca's Soriot, also added that he remained confident the company would deliver earnings for 2014 in line with the November 2013 consensus forecast (excluding ViroPharma).Others in the sector including Summit Corporation, Futura Medical and Skyepharma were making decent gains today.Vectura was also higher after the respiratory development company confirmed that its partner Sandoz has received Swedish marketing approval for their inhaler product AirFluSal Forspiro. Top performing sectors so far todayTechnology Hardware & Equipment 1,176.48 +1.16%Pharmaceuticals & Biotechnology 11,859.30 +0.85%Industrial Transportation 3,342.59 +0.78%Media 6,494.69 +0.73%Household Goods & Home Construction 11,269.09 +0.71%Bottom performing sectors so far todayElectronic & Electrical Equipment 4,505.01 -1.25%Industrial Metals & Mining 1,291.41 -1.24%Financial Services 7,863.20 -1.08%Oil & Gas Producers 8,257.45 -1.01%Forestry & Paper 10,922.16 -0.98%BC
More News
15 Dec 2016 12:38

Summit Therapeutics widens loss as drug development continues

(ShareCast News) - Drug discovery and development company Summit Therapeutics posted its financial results for the third quarter to 31 October on Thursday. The AIM-traded firm had cash and cash equivalents at period end of £34.6m compared to £16.3m on 31 January. Its loss for the nine months was £1

Read more
16 Nov 2016 12:28

Summit Therapeutics enrols first US patients in ezutromid trial for DMD

(ShareCast News) - AIM-listed drug discovery and development company Summit Therapeutics has enrolled its first patients in phase II proof of concept trials in the US of ezutromid in patients with Duchenne muscular dystrophy. Summit said enrolment and dosing of patients into Phase Out DMD in the UK

Read more
6 Oct 2016 14:28

Summit Therapeutics shares plummet despite positive progress

(ShareCast News) - Drug discovery and development company Summit Therapeutics presented preclinical data at the 21st International Congress of the World Muscle Society in Granada, Spain on Thursday, including further findings from its programme to develop tools to measure biomarkers of muscle health

Read more
4 Oct 2016 11:52

BUZZ-Summit Therapeutics: Best day since 2009 on Sarepta deal

** Shares in drug developer Summit Therapeutics up 58 pct after teams up with US drug co Sarepta Therapeutics to develop and market DMD drug in Europe ** Stock poised for its best day since April 2009 ** Co gets $40 mln upfront payment, could receive up to $522 million in milestone p

Read more
9 Aug 2016 11:51

Summit Therapeutics Sees Positive Phase I Trial Results For Ezutromid

Read more
21 Jun 2016 06:46

Summit Therapeutics Shows Further Positive Trial Data For Ridinilazole

Read more
17 Jun 2016 11:21

Summit Therapeutics Enrols First Patient In Phase II Ezutromid Trial

Read more
2 Jun 2016 14:30

Cash reduced, losses widen at Summit Therapeutics

(ShareCast News) - Drug discovery and development company Summit Therapeutics posted its first quarter results on Thursday, with cash reduced and losses widening. The AIM-traded firm, which is advancing therapies for Duchenne muscular dystrophy (DMD) and C. difficile infection (CDI), had cash and ca

Read more
10 May 2016 16:46

Losses widen at Summit Therapeutics

(ShareCast News) - Drug discovery and development company Summit Therapeutics reported an increase in cash and activities in its full-year results on Tuesday, though its losses widened as it carried its projects towards commercialisation. The AIM-traded firm had cash and cash equivalents of £16.3m o

Read more
10 May 2016 11:20

Summit Therapeutics Posts Widened Loss As It Progresses Programmes

Read more
28 Apr 2016 11:11

Summit Therapeutics Gets Further US Patent For Antibiotic Ridinlazole

Read more
26 Apr 2016 11:16

Summit Therapeutics Gets Clearance To Expand Ezutromid Trial To US

Read more
30 Mar 2016 12:48

Summit reports positive results from Duchenne muscular dystrophy treatment

(ShareCast News) - Summit Therapeutics reported positive interim findings on Wednesday, from a recent Phase 1 trial of a new oral formulation of its SMT C1100 therapy for Duchenne muscular dystrophy. The AIM-traded drug discovery and development company focuses on advancing therapies for Duchenne mu

Read more
30 Mar 2016 11:06

Summit Therapeutics Gets Positive Interim SMT C1100 Test Results

Read more
7 Mar 2016 12:43

Summit Therapeutics Sees Further Positive Data For Ridinilazole

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.